Fred Aslan - 18 Jul 2024 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Reporting relationship: President and CEO, Director
Issuer ticker: ARTV
Reported as of: 18 Jul 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Jul 2024, 20:18:50 UTC
Next SEC filing: 07 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Neha Krishnamohan, Attorney-in-Fact

Key filing fact

Fred Aslan filed Form 4 for Artiva Biotherapeutics, Inc. (ARTV) on 22 Jul 2024.

Key facts

This page summarizes Fred Aslan's Form 4 filing for Artiva Biotherapeutics, Inc. (ARTV).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 22 Jul 2024, 20:18.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARTV transaction

Common Stock

Award

Transaction value: $0
Shares: +228,905
Change %
Price: $0.000000
Shares after: 228,905
Date: 22 Jul 2024
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARTV transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +343,811
Change %
Price: $0.000000
Shares after: 343,811
Date: 18 Jul 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 343,811
Exercise price: $12.00
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.

Footnote F2

25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .